Surgery Websites
Transplant Surgery »  Meet the Team »  Nephrology »  Flavio Vincenti, M.D.
Flavio Vincenti, M.D.

Flavio Vincenti, M.D.

Clinical Professor of Medicine and Surgery
Departments of Medicine and Surgery
Endowed Chair in Kidney Transplantation

Contact Information

Academic Office
(415) 353-8390
Fax: 415.353.8974
flavio.Vincenti@ucsfmedctr.org

Appointments
(415) 353-1888 Liver
(415) 353-1551 Kidney and Pancreas
Open Popup
  • American University Medical Center of Beirut, BS  - 1971
  • Universite Saint-Joseph Faculty of Medicine, MD - 1975
  • Internal Medicine Residency: American University of Beirut Medical Center
  • Fellow in Nephrology, Emory University School of Medicine, Atlanta, Georgia, July 1, 1973 - June 30, 1975
  • Research Fellow, National Kidney Foundation, July 1, 1974 - June 30, 1975
  • Fellow in Cardiovascular Research Institute (Nephrology) University of California, San Francisco, July 1, 1975 - June 30, 1976
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Nephrology - Subspecialty
  • Chronic Kidney Disease
  • End Stage Renal Disease (Kidney Failure)
  • Internal Medicine
  • Kidney Transplantation
  • Living Kidney Donor Transplantation
  • Pancreas Transplantation
  • Transplant Nephrology
  • Transplant Nephrology

Dr. Flavio Vincenti, a kidney and pancreas transplant specialist, is board certified in internal medicine and nephrology. He came to UCSF Medical Center in 1975 for a transplant nephrology fellowship and was appointed a member of the kidney transplant team.

His memberships in professional organizations include the American Society of Nephrology, American Society of Transplantation, International Society of Nephrology and Transplantation Society. He is a co-leader of the kidney section of the Immune Tolerance Network for kidney transplantation. In addition, he is on the editorial board of the American Journal of Kidney Diseases and Graft.

In 1978, Vincenti was one of the authors of an article in the New England Journal of Medicine about the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and author on the use of anti interleukin 2 receptor monoclonal antibodies. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Data provided by UCSF Profiles, powered by CTSI
  • Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 2014
    -
    May 2024
    Principal Investigator
  • Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 2014
    -
    Jun 2021
    Principal Investigator
  • General Clinical Research Center
    Sponsor:
    Sponsor ID:
    Funding Period:
    Dec 1974
    -
    Mar 2009
    Co-Investigator
Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 266
Data provided by UCSF Profiles, powered by CTSI
  1. Lee LM, Zhang H, Lee K, Liang H, Merleev A, Vincenti F, Maverakis E, Thomson AW, Tang Q. A Comparison of Ex Vivo Expanded Human Regulatory T Cells Using Allogeneic Stimulated B Cells or Monocyte-Derived Dendritic Cells. Front Immunol. 2021; 12:679675. View in PubMed
  2. Danovitch GM, Bunnapradist S, Cohen D, Hariharan S, McKay D, Ratner L, Stegall MD, Steiner RW, Stock PG, Vincenti F. Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs. Am J Transplant. 2021 Jun 03. View in PubMed
  3. Zarinsefat A, Hartoularos G, Rychkov D, Rashmi P, Chandran S, Vincenti F, Yee CJ, Sarwal MM. Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation. Front Genet. 2020; 11:610682. View in PubMed
  4. Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial. Am J Transplant. 2021 07; 21(7):2543-2554. View in PubMed
  5. Vincenti F, Kim J, Gouveia D, Pelle G, Mayne TJ, Neylan JF. Phase 3 trial Design of the Hepatocyte Growth Factor Mimetic ANG-3777 in Renal Transplant Recipients With Delayed Graft Function. Kidney Int Rep. 2021 Feb; 6(2):296-303. View in PubMed
  6. View All Publications

 

Site Directory
    X